Xiaowei Xu

34.6k citations

202 papers · 9.8k indexed · 4 hit papers · h-index 53

Impact in

Oncology top 0.2%
- Cutaneous Melanoma Detection and Management
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Immunology top 0.5%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer

Papers in

Oncology 100
- Cutaneous Melanoma Detection and Management 45
- CAR-T cell therapy research 25
- Cancer Immunotherapy and Biomarkers 22
- Cancer Cells and Metastasis 13
Immunology 56
- Immunotherapy and Immune Responses 38
- Immune Cell Function and Interaction 14

Co-authors: Meenhard Herlyn David E. Elder Shujing Liu Thiennga K. NguyenSuresh KumarLynn M. Schuchter Giorgos C. Karakousis Géza Ács
Journals: Cancer Research (10 papers)Clinical Cancer Research (9 papers)Journal of Cutaneous Pathology (8 papers)Annals of Surgical Oncology (7 papers)Journal of Clinical Oncology (7 papers)
Partner nations: United States China Australia

In The Last Decade

Xiaowei Xu

189 papers receiving 9.6k citations

Hit Papers

align trajectories log scale

Inferring super-resolution tissue architecture by integrating spatial transcriptomics with histology 2024 · 73 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2024 Nature Biotechnology
2020 Immunity
2017 Cancer Cell
2005 Cancer Research

Peers

Countries citing papers authored by Xiaowei Xu

Since Specialization

Citations

This map shows the geographic impact of Xiaowei Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaowei Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaowei Xu more than expected).

Fields of papers citing papers by Xiaowei Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaowei Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaowei Xu. The network helps show where Xiaowei Xu may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Xiaowei Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Xiaowei Xu Line = papers co-authored together Xiaowei Xu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Unraveling the interfacial homogeneity and bulk crystallization for efficient and stable perovskite solar cells via ionic liquids Energy & Environmental Science ·Xiaowei Xu, Sibo Li, Chengwei Shan, Xiaoyu Gu, Jie Zeng, Wenbo Peng, Ivan Luiz Goncalves Pinto, Wuyi Mao, Yuanqiang Chen, Erjun Zhou, Chen Xie, Yong Zhang, Longbin Qiu, Seman Kamaruzzaman, Aung Ko Ko Kyaw	2025	12
2	PTRF Confers Melanoma‐Acquired Drug Resistance Through the Upregulation of EGFR Cell Proliferation ·Miao Wang, Ying Cao, Chengcheng Ren, Ke Wang, Yaxiang Wang, Xiaoying Wu, Jian Mao, Qian Liang, Qian Zhang, Hezhe Lu, Xiaowei Xu, Yu‐Sheng Cong	2025	0
3	Pan-tumor harmonization of pathologic response assessment for standardized data collection in neoadjuvant IO trials (PATHdata): Final analysis of a multi-institutional reproducibility study. Journal of Clinical Oncology ·Julie S. Deutsch, Tricia R. Cottrell, Krista Y. Chen, Carlos E. de Andrea, Ezra Baraban, Pierre Fiset, Jaroslaw Jedrych, 洋明石上, Roberto Salgado, Christian M. Schürch, Richard A. Scolyer, Raja R. Seethala, Lynette M. Sholl, Sabina Signoretti, Michael T. Tetzlaff, Annikka Weissferdt, Xiaowei Xu, James Ziai, Ashley Cimino‐Mathews, Janis M. Taube	2024	0
4	Inferring super-resolution tissue architecture by integrating spatial transcriptomics with histology Nature Biotechnology ·Daiwei Zhang, Amelia Schroeder, Hanying Yan, Алябина Е. В., Jian Hu, Michelle Y. Y. Lee, Hayat Adinov, Katalin Suszták, Xiaowei Xu, Michael D. Feldman, Edward B. Lee, Emma E. Furth, Linghua Wang, Mingyao Li Hit paper breakdown →	2024	73
5	Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors Cancer Research ·Wenqun Zhong, Zebin Xiao, B. Parol, Chelsea L. Anderson, Nathan Redlich, Ziyan Yu, Zara Stiener, Neil C. Sheppard, Serge Y. Fuchs, Xiaowei Xu, Meenhard Herlyn, Carl H. June, Ellen Puré, Wei Guo	2023	39
6	Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma Molecular Cancer Therapeutics ·Su-Shien Ho, Signe Caksa, Yong-Soo Jang, Nicole A. Wilski, Jianzhao Cao, Inna Chervoneva, Keith T. Flaherty, Meenhard Herlyn, Xiaowei Xu, Andrew E. Aplin, Claudia Capparelli	2023	8
7	Relationship between PAH4 formation and thermal reaction products in model lipids and possible pathways of PAHs formation Journal of Hazardous Materials ·Yasu Zhang, Xiaofang Liu, Shuai Wang, 諭米澤, Jixian Zhang, Li Liang, Chaoting Wen, Youdong Li, Xiaowei Xu, Xudong He, Guoyan Liu, Xin Xu	2023	14
8	Role of nuclear localization in the regulation and function of T-bet and Eomes in exhausted CD8 T cells Cell Reports ·Laura M. McLane, Shin Foong Ngiow, Zeyu Chen, John Attanasio, Sasikanth Manne, Gordon Ruthel, Jennifer E. Wu, Ryan P. Staupe, Wei Xu, Ravi K. Amaravadi, Xiaowei Xu, Giorgos C. Karakousis, Tara C. Mitchell, Lynn M. Schuchter, Alexander C. Huang, Bruce D. Freedman, Michael R. Betts, E. John Wherry	2021	77
9	sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients Clinical Cancer Research ·Mitchell E. Fane, Brett L. Ecker, Amanpreet Kaur, Gloria E. Marino, Gretchen M. Alicea, Stephen M. Douglass, Yash Chhabra, Marie R. Webster, Andrea Marshall, Richard Colling, T.F.T., Nicholas Coupe, Hisato Hara, Leticia Campo, Mark R. Middleton, Pippa Corrie, Xiaowei Xu, Giorgos C. Karakousis, Ashani T. Weeraratna	2020	22
10	TRAF6 Activates Fibroblasts to Cancer-Associated Fibroblasts through FGF19 in Tumor Microenvironment to Benefit the Malignant Phenotype of Melanoma Cells Journal of Investigative Dermatology ·Yeye Guo, Xu Zhang, Weiqi Zeng, Jianglin Zhang, Wenxuan Yang, Zeyu Wu, Juan Su, Yi Xiao, William Sydney Stock, Ling Tang, Xiaowei Xu, Xiang Chen, Cong Peng	2020	20
11	Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma Clinical Cancer Research ·Naomi B. Haas, Leonard J. Appleman, Mark N. Stein, Maryann Redlinger, Svante Svensson, Xiaowei Xu, Angelique Onorati, Juan Ceballos-Corral, Tae Hyong Kim, Chao Jie Zhen, Sabah Kadri, Jeremy P. Segal, Phyllis A. Gimotty, Lisa E. Davis, Ravi K. Amaravadi	2019	112
12	Age-Related Changes in HAPLN1 Increase Lymphatic Permeability and Affect Routes of Melanoma Metastasis Cancer Discovery ·Brett L. Ecker, Amanpreet Kaur, Stephen M. Douglass, Marie R. Webster, Filipe V. Almeida, Gloria E. Marino, Andrew J. Sinnamon, 宇都宮勇人, Gretchen M. Alicea, Abibatou Ndoye, Mitchell E. Fane, Xiaowei Xu, Myung‐Shin Sim, Gary B. Deutsch, Mark B. Faries, Giorgos C. Karakousis, Ashani T. Weeraratna	2018	113
13	A Designer Cross-reactive DNA Immunotherapeutic Vaccine that Targets Multiple MAGE-A Family Members Simultaneously for Cancer Therapy Clinical Cancer Research ·Elizabeth K. Duperret, Shujing Liu, Megan Paik, Emily Garcia, Regina Stoltz, Xiaoming Liu, Siti Aishah Abdul Wahab, Alfredo Perales‐Puchalt, Charles C. Reed, Jian Yan, Xiaowei Xu, David B. Weiner	2018	36
14	Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer Cancer Research ·Dongmei Zhang, Gao Zhang, Zhongyi Hu, Lawrence W. Wu, Yi Feng, R Oyen, Youyou Zhang, Lu Yang, Tian Tian, Weiting Xu, Zhi Wei, Yiling Lu, Keith T. Flaherty, Xiaomin Zhong, Gordon B. Mills, Phyllis A. Gimotty, Xiaowei Xu, Meenhard Herlyn, Lin Zhang	2017	29
15	HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors Cancer Research ·Anna Budina-Kolomets, Marie R. Webster, Julia I-Ju Leu, Matthew Jennis, Clemens Krepler, Greg L. Miller, Andrew V. Kossenkov, Wei Xu, Giorgos C. Karakousis, Lynn M. Schuchter, Ravi K. Amaravadi, Hong Wu, Xiangfan Yin, Qin Liu, Yiling Lu, Gordon B. Mills, Xiaowei Xu, Donna L. George, Ashani T. Weeraratna, Maureen E. Murphy	2016	34
16	Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors Clinical Cancer Research ·Yan Kong, Lu Si, Yiqian Li, Xiaowen Wu, Xiaowei Xu, Jie Dai, Huan Tang, Meng Ma, Zhihong Chi, Xinan Sheng, Chuanliang Cui, Jun Guo	2015	58
17	Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib Clinical Cancer Research ·Jie Dai, Yan Kong, Lu Si, Zhihong Chi, Chuanliang Cui, Xinan Sheng, Lili Mao, Siming Li, Bin Lian, Ruifeng Yang, Shujing Liu, Xiaowei Xu, Jun Guo	2013	38
18	Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma Clinical Cancer Research ·F. Sola, Lu Si, Yanyan Zhu, Xiaowei Xu, Christopher L. Corless, Keith T. Flaherty, Li Li, Haifu Li, Xinan Sheng, Chuanliang Cui, Zhihong Chi, Siming Li, Mei Han, Lili Mao, Aiping Lü, Jun Guo	2011	181
19	Disabling TNF receptor signaling by induced conformational perturbation of tryptophan-107 Proceedings of the National Academy of Sciences ·Ramachandran Murali, Xin Cheng, Alan Berezov, Xiulian Du, Lawrence E. Sellers, Ernesto Freire, Xiaowei Xu, Youhai H. Chen, Mark I. Greene	2005	38
20	Scarring alopecia associated with mastocytosis Journal of Cutaneous Pathology ·Xiaowei Xu, R. T. Apple, Rosalie Elenitsas, George Cotsarelis	2003	13

About Xiaowei Xu

Xiaowei Xu is a scholar working on Oncology, Immunology, Immunology and Allergy, Cancer Research and Transplantation, having authored 202 papers that have together received 9.8k indexed citations. Recurring topics across this work include Cutaneous Melanoma Detection and Management (45 papers), Immunotherapy and Immune Responses (38 papers), CAR-T cell therapy research (25 papers), Cancer Immunotherapy and Biomarkers (22 papers), Melanoma and MAPK Pathways (16 papers), Immune Cell Function and Interaction (14 papers), Cancer Cells and Metastasis (13 papers) and Cell Adhesion Molecules Research (12 papers). The work is most often cited by research in Oncology (4.9k citations), Immunology (2.7k citations), Cancer Research (1.9k citations), Molecular Biology (4.7k citations) and Dermatology (526 citations). Xiaowei Xu has collaborated with scholars based in United States, China and Australia. Frequent co-authors include Meenhard Herlyn, David E. Elder, Shujing Liu, Thiennga K. Nguyen, Suresh Kumar, Lynn M. Schuchter, Giorgos C. Karakousis, Géza Ács, Phyllis A. Gimotty and Ravi K. Amaravadi. Their work appears in journals such as Cancer Research, Clinical Cancer Research, Journal of Cutaneous Pathology, Annals of Surgical Oncology and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact